Skip to main content
main-content
Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases 9/2022

08.08.2022 | Original Article

Ceftazidime–avibactam treatment in bacteremia caused by OXA-48 carbapenemase-producing Klebsiella pneumoniae

verfasst von: O. Lima, A. Sousa, R. Longueira-Suárez, A. Filgueira, C. Taboada-Martínez, C. Portela-Pino, A. Nodar, F. Vasallo-Vidal, L. Martinez-Lamas, A. Pérez-Landeiro, M. Rubianes, MT. Pérez-Rodríguez

Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases | Ausgabe 9/2022

Einloggen, um Zugang zu erhalten

Abstract

Therapeutic options for bacteremia caused by carbapenem-resistant Enterobacterales (CRE) OXA-48-type are limited. The objective of this study was to analyze clinical success of CAZ-AVI compared with best available therapy (BAT) in patients with Klebsiella pneumoniae carbapenemase-producing OXA-48-type bacteremia (CRKp-OXA-48). We conducted a retrospective, single-center observational study in adult patients with CRKp-OXA-48 between December 2015 and May 2019. We collected the patients’ clinical and epidemiological characteristics, antibiotic treatment (CAZ-AVI vs. BAT), and evolution. Factors associated with clinical success were analyzed using binary logistic regression. The study included 76 patients with CRKp-OXA-48-type bacteremia 33 received CAZ-AVI and 43 BAT. CAZ-AVI was mainly used in monotherapy (91%). Clinical success was more common in patients < 70-year-old (OR 4.79, 95% CI [1.435–16.002], p = 0.011) and CAZ-AVI treatment (OR 6.69, 95% CI [1.68–26.604], p = 0.007). Kaplan–Meier survival curve of 14-day mortality showed a lower mortality in patients who received CAZ-AVI (log rank 0.013). However, CAZ-AVI did not achieve statistical difference in IPTW for 14- and 30-day mortality (aOR 0.1, 95% CI [0.02–1.22], p = 0.076 and aOR 1.7, 95% CI [0.48–5.98], p = 0.413, respectively). CAZ-AVI treatment might be associated with a greater clinical success in CRKp-OXA-48 bacteremia.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
9.
Zurück zum Zitat Tumbarello M, Viale P, Viscoli C, Trecarichi EM, Tumietto F, Marchese A et al (2012) Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin Infect Dis Off Publ Infect Dis Soc Am 55:943–50. https://​doi.​org/​10.​1093/​cid/​cis588 CrossRef Tumbarello M, Viale P, Viscoli C, Trecarichi EM, Tumietto F, Marchese A et al (2012) Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin Infect Dis Off Publ Infect Dis Soc Am 55:943–50. https://​doi.​org/​10.​1093/​cid/​cis588 CrossRef
22.
Zurück zum Zitat Pérez-Rodríguez MT, Sousa A, López-Cortés LE, Martínez-Lamas L, Val N, Baroja A et al (2019) Moving beyond unsolicited consultation: additional impact of a structured intervention on mortality in Staphylococcus aureus bacteraemia. J Antimicrob Chemother 1(74):1101–1107. https://​doi.​org/​10.​1093/​jac/​dky556 CrossRef Pérez-Rodríguez MT, Sousa A, López-Cortés LE, Martínez-Lamas L, Val N, Baroja A et al (2019) Moving beyond unsolicited consultation: additional impact of a structured intervention on mortality in Staphylococcus aureus bacteraemia. J Antimicrob Chemother 1(74):1101–1107. https://​doi.​org/​10.​1093/​jac/​dky556 CrossRef
23.
Zurück zum Zitat Tumbarello M, Trecarichi EM, Corona A, De Rosa FG, Bassetti M, Mussini C et al (2019) Efficacy of ceftazidime-avibactam salvage therapy in patients with infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae. Clin Infect Dis Off Publ Infect Dis Soc Am 68:355–64. https://​doi.​org/​10.​1093/​cid/​ciy492 CrossRef Tumbarello M, Trecarichi EM, Corona A, De Rosa FG, Bassetti M, Mussini C et al (2019) Efficacy of ceftazidime-avibactam salvage therapy in patients with infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae. Clin Infect Dis Off Publ Infect Dis Soc Am 68:355–64. https://​doi.​org/​10.​1093/​cid/​ciy492 CrossRef
29.
Zurück zum Zitat Weinstein MP (2018) M100-performance standards for antimicrobial susceptibility testing, 28th edition. Clin Lab Weinstein MP (2018) M100-performance standards for antimicrobial susceptibility testing, 28th edition. Clin Lab
34.
Zurück zum Zitat Cano A, Gutiérrez-Gutiérrez B, Machuca I, Gracia-Ahufinger I, Pérez-Nadales E, Causse M et al (2018) Risks of Infection and mortality among patients colonized With Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: validation of scores and proposal for management. Clin Infect Dis Off Publ Infect Dis Soc Am 66:1204–10. https://​doi.​org/​10.​1093/​cid/​cix991 CrossRef Cano A, Gutiérrez-Gutiérrez B, Machuca I, Gracia-Ahufinger I, Pérez-Nadales E, Causse M et al (2018) Risks of Infection and mortality among patients colonized With Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: validation of scores and proposal for management. Clin Infect Dis Off Publ Infect Dis Soc Am 66:1204–10. https://​doi.​org/​10.​1093/​cid/​cix991 CrossRef
35.
Zurück zum Zitat Giannella M, Trecarichi EM, De Rosa FG, Del Bono V, Bassetti M, Lewis RE et al (2014) Risk factors for carbapenem-resistant Klebsiella pneumoniae bloodstream infection among rectal carriers: a prospective observational multicentre study. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis 20:1357–1362. https://​doi.​org/​10.​1111/​1469-0691.​12747 CrossRef Giannella M, Trecarichi EM, De Rosa FG, Del Bono V, Bassetti M, Lewis RE et al (2014) Risk factors for carbapenem-resistant Klebsiella pneumoniae bloodstream infection among rectal carriers: a prospective observational multicentre study. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis 20:1357–1362. https://​doi.​org/​10.​1111/​1469-0691.​12747 CrossRef
36.
Zurück zum Zitat Fiore M, Alfieri A, Di Franco S, Pace MC, Simeon V, Ingoglia G et al (2020) Ceftazidime-avibactam combination therapy compared to ceftazidime-avibactam monotherapy for the treatment of severe infections due to carbapenem-resistant pathogens: a systematic review and network meta-analysis. Antibiot Basel Switz 7:9. https://​doi.​org/​10.​3390/​antibiotics90703​88 CrossRef Fiore M, Alfieri A, Di Franco S, Pace MC, Simeon V, Ingoglia G et al (2020) Ceftazidime-avibactam combination therapy compared to ceftazidime-avibactam monotherapy for the treatment of severe infections due to carbapenem-resistant pathogens: a systematic review and network meta-analysis. Antibiot Basel Switz 7:9. https://​doi.​org/​10.​3390/​antibiotics90703​88 CrossRef
38.
Zurück zum Zitat Shields RK, Potoski BA, Haidar G, Hao B, Doi Y, Chen L et al (2016) Clinical outcomes, drug toxicity, and emergence of ceftazidime-avibactam resistance among patients treated for carbapenem-resistant Enterobacteriaceae infections. Clin Infect Dis Off Publ Infect Dis Soc Am 15(63):1615–1618. https://​doi.​org/​10.​1093/​cid/​ciw636 CrossRef Shields RK, Potoski BA, Haidar G, Hao B, Doi Y, Chen L et al (2016) Clinical outcomes, drug toxicity, and emergence of ceftazidime-avibactam resistance among patients treated for carbapenem-resistant Enterobacteriaceae infections. Clin Infect Dis Off Publ Infect Dis Soc Am 15(63):1615–1618. https://​doi.​org/​10.​1093/​cid/​ciw636 CrossRef
Metadaten
Titel
Ceftazidime–avibactam treatment in bacteremia caused by OXA-48 carbapenemase-producing Klebsiella pneumoniae
verfasst von
O. Lima
A. Sousa
R. Longueira-Suárez
A. Filgueira
C. Taboada-Martínez
C. Portela-Pino
A. Nodar
F. Vasallo-Vidal
L. Martinez-Lamas
A. Pérez-Landeiro
M. Rubianes
MT. Pérez-Rodríguez
Publikationsdatum
08.08.2022
Verlag
Springer Berlin Heidelberg
Erschienen in
European Journal of Clinical Microbiology & Infectious Diseases / Ausgabe 9/2022
Print ISSN: 0934-9723
Elektronische ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-022-04482-9

Weitere Artikel der Ausgabe 9/2022

European Journal of Clinical Microbiology & Infectious Diseases 9/2022 Zur Ausgabe

Neu im Fachgebiet Innere Medizin

Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Innere Medizin und bleiben Sie gut informiert – ganz bequem per eMail.